615. Is Ozempic as Magical as It Sounds?

Key takeaways

Direct-to-consumer pharmaceutical advertising is prevalent in the U.S., impacting the success of drug sales.
GLP-1 drugs offer significant benefits for diabetes and obesity but raise concerns over long-term effectiveness and accessibility.
Ezekiel Emanuel criticizes the current structure of the U.S. healthcare system for disincentivizing long-term health investments.
Global drug coverage for GLP-1 medications varies significantly, reflecting different healthcare priorities and policies.
Innovations like AI and telehealth are key to improving healthcare access and efficiency but require careful implementation and regulation.

Summary

The U.S. Pharmaceutical Advertising Landscape

In the U.S., pharmaceutical companies can advertise directly to consumers, a practice shared only with New Zealand. While such advertising is prevalent, notably for drugs like Ozempic, its success isn't guaranteed due to the high costs associated with drug development. Blockbuster drugs, earning over a billion dollars annually, are crucial to the industry's financial viability.

GLP-1 Drugs: More than Meets the Eye

GLP-1 drugs, particularly Ozempic and Wegovy, were initially developed for diabetes treatment but have gained popularity due to their side effect of weight loss—especially pertinent in a country with high obesity rates. Despite enthusiasm among prescribers and patients, there are concerns about long-term effects and high costs limiting access.

Ezekiel Emanuel's Insights on Healthcare

Ezekiel Emanuel, an influential figure in healthcare policy, discusses the insurance industry's reluctance to cover GLP-1 medications, highlighting that the current structure incentivizes short-term savings rather than long-term health investments. Emanuel candidly reviews the flaws and complexities of the U.S. healthcare system, including the 'churn' effect of insurance coverage tied to employment instability.

Global Perspectives on GLP-1 Drug Coverage

Comparison of U.S. GLP-1 drug coverage with other high-income countries reveals a patchwork of policies. Many countries do not reimburse for weight loss, citing cost-effectiveness concerns, while Emanuel argues that the potential long-term health benefits warrant a reevaluation of coverage.

The Future of Healthcare and Innovative Solutions

The conversation touches on innovations in healthcare, including AI and telemedicine, which hold promise for improving patient care and reducing costs. Emanuel stresses the need for collaboration between public and private sectors while also advocating for transforming the healthcare system to ensure better access and efficiency in treatment.

Show notes

In a wide-ranging conversation with Ezekiel Emanuel, the policymaking physician and medical gadfly, we discuss the massive effects of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. We also talk about the state of cancer care, mysteries in the gut microbiome, flaws in the U.S. healthcare system — and what a second Trump term means for healthcare policy.

SOURCES:
- Ezekiel Emanuel, vice provost for Global Initiatives, co-director of the Health Transformation Institute, and professor at the University of Pennsylvania Perelman School of Medicine.

RESOURCES:
- "Obesity Drugs Would Be Covered by Medicare and Medicaid Under Biden Proposal," by Margot Sanger-Katz (The New York Times, 2024).
- "International Coverage of GLP-1 Receptor Agonists: A Review and Ethical Analysis of Discordant Approaches," by Johan L. Dellgren, and Govind Persad, and Ezekiel J. Emanuel (The Lancet, 2024).
- The Coming Wave: Technology, Power, and the Twenty-first Century's Greatest Dilemma, by Mustafa Suleyman (2023).
- "The Significance of Blockbusters in the Pharmaceutical Industry," by Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, Dominik Hartl, and Oliver Gassmann (Nature Reviews Drug Discovery, 2022).
- Reinventing American Health Care: How the Affordable Care Act Will Improve Our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System, by Ezekiel J. Emanuel (2014).
- "Why I Hope to Die at 75," by Ezekiel J. Emanuel (The Atlantic, 2014).
- "Direct-to-Consumer Advertising of Pharmaceuticals," by Ziad F. Gellad and Kenneth W. Lyles (The American Journal of Medicine, 2014).
- Brothers Emanuel: A Memoir of an American Family, by Ezekiel J. Emanuel (2013).
- "Bounds in Competing Risks Models and the War on Cancer," by Bo E. Honoré and Adriana Lleras-Muney (Econometrica, 2006).

EXTRAS:
- "How to Fix Medical Research," by People I (Mostly) Admire (2024).
- "The Suddenly Diplomatic Rahm Emanuel," by Freakonomics Radio (2023).
- "Ari Emanuel Is Never Indifferent," by Freakonomics Radio (2023).
- "Who Pays for Multimillion-Dollar Miracle Cures?" by Freakonomics, M.D. (2023).
- "Who Gets the Ventilator?" by Freakonomics Radio (2020).

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.